BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 6148712)

  • 1. Antipsychotic efficacy of fluperlapine. An open multicenter trial.
    Woggon B; Angst J; Bartels M; Heinrich K; Hippius H; Koukkou M; Krebs E; Küfferle B; Müller-Oerlinghausen B; Pöldinger W
    Neuropsychobiology; 1984; 11(2):116-20. PubMed ID: 6148712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a multicenter AMDP study with fluperlapine in schizophrenic patients.
    Woggon B; Heinrich K; Küfferle B; Müller-Oerlinghausen B; Pöldinger W; Rüther E; Schied HW
    Arzneimittelforschung; 1984; 34(1A):122-4. PubMed ID: 6145427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of a new dibenzo-epine neuroleptic compared with haloperidol. Results of an open and crossover study.
    Mann K; Bartels M; Gärtner HJ; Schied HW; Wagner W; Heimann H
    Pharmacopsychiatry; 1987 Jul; 20(4):155-9. PubMed ID: 2886997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Partial response to antipsychotic treatment: the patient with enduring symptoms.
    Emsley RA
    J Clin Psychiatry; 1999; 60 Suppl 23():10-3. PubMed ID: 10625194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
    Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
    Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clozapine for refractory schizophrenia: an open study of 14 patients treated up to 2 years.
    Mattes JA
    J Clin Psychiatry; 1989 Oct; 50(10):389-91. PubMed ID: 2571612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of extrapyramidal side effects with terguride.
    Filip V; Marsálek M; Hálková E; Karen P
    Psychiatry Res; 1992 Jan; 41(1):9-16. PubMed ID: 1348584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duration of a clozapine trial in neuroleptic-resistant schizophrenia.
    Meltzer HY
    Arch Gen Psychiatry; 1989 Jul; 46(7):672. PubMed ID: 2567591
    [No Abstract]   [Full Text] [Related]  

  • 9. Fluperlapine in 104 schizophrenic patients. Open multicenter trial.
    Fischer-Cornelssen KA
    Arzneimittelforschung; 1984; 34(1A):125-30. PubMed ID: 6145428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis.
    Small JG; Milstein V; Marhenke JD; Hall DD; Kellams JJ
    J Clin Psychiatry; 1987 Jul; 48(7):263-7. PubMed ID: 2885310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder.
    Elie D; Poirier M; Chianetta J; Durand M; Grégoire C; Grignon S
    J Psychopharmacol; 2010 Jul; 24(7):1037-44. PubMed ID: 19164494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of zuclopenthixol acetate on psychotic anxiety evaluated in an open study].
    Romain JL; Dermain P; Greslé P; Grignon S; Moisan P; Nore D; Pech G; Benyaya J; Perret I
    Encephale; 1996; 22(4):280-6. PubMed ID: 9035983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New chemotherapy approaches to psychoses].
    Olié JP; Baylé FJ
    Encephale; 1997 Apr; 23 Spec No 2():2-9. PubMed ID: 9273302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
    Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME
    Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. All antipsychotics are equal, but some are more equal than others.
    Volavka J; Citrome L
    J Clin Psychiatry; 2009 Mar; 70(3):429-30. PubMed ID: 19317959
    [No Abstract]   [Full Text] [Related]  

  • 16. Fluperlapine in tardive dyskinesia and parkinsonism.
    Korsgaard S; Noring U; Gerlach J
    Psychopharmacology (Berl); 1984; 84(1):76-9. PubMed ID: 6149595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-acting injectable risperidone in treatment refractory patients: a 14-week open-label pilot study.
    Procyshyn RM; Barr AM; Flynn S; Schenk C; Ganesan S; Honer WG
    Schizophr Res; 2010 Nov; 123(2-3):273-5. PubMed ID: 20688481
    [No Abstract]   [Full Text] [Related]  

  • 18. Investigation of the effect of fluperlapine on the EEG in schizophrenic patients.
    Ferber G; Matejcek M; Krebs E; Friedmann R
    Neuropsychobiology; 1987; 18(1):43-50. PubMed ID: 2895433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
    Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compliance and schizophrenia: the predictive potential of insight into illness, symptoms, and side effects.
    Kao YC; Liu YP
    Compr Psychiatry; 2010; 51(6):557-65. PubMed ID: 20965300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.